[Antilipemic agents and atherothrombosis. Effects of antilipemic agents on blood platelet function, coagulation and fibrinolysis].
Sinzinger
H
H
Klinik für Nuklearmedizin, Universität Wien. helmut.sinzinger@akh_wien.ac.at
D000924:Anticholesteremic Agents / Q000494:pharmacology; D017920:Antiporters / Q000494:pharmacology; D001161:Arteriosclerosis / Q000097:blood / Q000517:prevention & control*; D001629:Bezafibrate / Q000494:pharmacology; D001777:Blood Coagulation / Q000187:drug effects*; D001779:Blood Coagulation Factors / Q000187:drug effects; D001792:Blood Platelets / Q000187:drug effects*; D002986:Clinical Trials as Topic; D002995:Clofibric Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D011345:Fenofibrate / Q000494:pharmacology; D005342:Fibrinolysis / Q000187:drug effects; D015248:Gemfibrozil / Q000494:pharmacology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D008148:Lovastatin / Q000494:pharmacology; D009525:Niacin / Q000494:pharmacology; D017035:Pravastatin / Q000494:pharmacology; D012307:Risk Factors; D019821:Simvastatin / Q000494:pharmacology; D013927:Thrombosis / Q000097:blood / Q000517:prevention & control*
D000924:Anticholesteremic Agents; D017920:Antiporters; D001779:Blood Coagulation Factors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; C009746:etofibrate; D009525:Niacin; D002995:Clofibric Acid; D008148:Lovastatin; D019821:Simvastatin; D017035:Pravastatin; D015248:Gemfibrozil; D011345:Fenofibrate; D001629:Bezafibrate